Last reviewed · How we verify

EMONO

Air Liquide Santé International · Phase 3 active Small molecule

EMONO is a medical gas mixture (likely nitric oxide-based) designed to improve oxygenation and reduce pulmonary hypertension in critically ill patients.

EMONO is a medical gas mixture (likely nitric oxide-based) designed to improve oxygenation and reduce pulmonary hypertension in critically ill patients. Used for Acute respiratory distress syndrome (ARDS) or severe hypoxemia (Phase 3 indication pending confirmation).

At a glance

Generic nameEMONO
Also known asNitrous Oxide/Oxygen, Nitrous oxide
SponsorAir Liquide Santé International
Drug classTherapeutic gas
ModalitySmall molecule
Therapeutic areaCritical Care / Pulmonary
PhasePhase 3

Mechanism of action

Air Liquide Santé International's EMONO appears to be a therapeutic gas product, potentially containing nitric oxide or similar gaseous agents that act on vascular endothelium to promote vasodilation and improve gas exchange. The exact mechanism requires confirmation from clinical trial data, but therapeutic gases in this class typically work by modulating nitric oxide signaling pathways or improving oxygen delivery to tissues.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results